AlloSource, Humacyte manufacturing partner to create bioengineered blood vessels from tissue donor cells
It is newly reported that AlloSource, largest non-profit providers of skin, bone and soft tissue allografts and the globe’s largest processor of cellular bone allografts, and Humacyte, Inc., have professionally entered into a long-term strategic manufacturing partnership. Humacyte, Inc., is considered to be pioneer in regenerative medicine pursuing development of investigational bioengineered blood vessels. By this latest potent agreement, AlloSource would become the sole manufacturing partner to expediently marvel Humacyte’s investigational bioengineered blood vessels being created for hemodialysis applications. The first investigational bioengineered vessel is marveled with the target of approval for use in patients with chronic kidney disease.